Aspergillosis refers to the spectrum of disease caused by members of the genus Aspergillus (see Table below). The three principal entities are: allergic bronchopulmonary aspergillosis (ABPA), pulmonary aspergilloma (fungus ball), and invasive aspergillosis . Colonization of the respiratory tract is also common. The clinical manifestation and severity of the disease depends upon the immunologic state of the patient . Lowered host resistance due to such factors as underlying debilitating disease, neutropenia chemotherapy, disruption of normal flora, and an inflammatory response due to the use of antimicrobial agents and steroids can predispose the patient to colonization, invasive disease, or both [458, 830, 1581]. Aspergillus spp. are frequently secondary opportunistic pathogens in patients with bronchiectasis, carcinoma, other mycoses, sarcoid, and tuberculosis [779, 2081, 2148].
Special resources: You may want to refer to the Infectious Disease Society of America (IDSA) Practice Guidelines for this disease available on the IDSA website. In addition, The Aspergillus web site offers an in-depth look into all aspects of invasive aspergillosis.
Forms of the disease
|Allergic bronchopulmonary aspergillosis (ABPA)||Sinuses, lungs|
|Pulmonary aspergilloma||Pre-existing lung cavity|
|Invasive aspergillosis||– Pulmonary aspergillosis (most common site of primary disease)
– CNS aspergillosis
– Sinonasal aspergillosis
– Renal abscesses
|Others||– Cutaneous: burns, post surgical wounds, IV insertion sites, etc.
– Exogenous endophthalmitis
– Allergic fungal sinusitis
– Urinary tract fungus balls
Prognosis and therapy
Prognosis depends upon the type and severity of disease as well as the immunological status of the patient . Allergic aspergillosis is typically a chronic entity, but evolves from episodes of acute corticosteroid-responsive asthma to fibrotic end-stage lung disease . Allergic aspergillosis has been successfully treated with corticosteroids, and intraconazole . The prolonged use of steroids in cases of chronic aspergillosis should be approached with caution .
Aspergillomas may be treated by surgical resection [575, 1163]. However, this approach may cause significant morbidity and mortality, therefore it should be reserved for patients at high risk to develop severe hemoptysis [852, 1462].
Invasive aspergillosis may be treated with voriconazole , isavuconazole, voriconazole in combination with an echinocandin, amphotericin B (deoxycholate and lipid preparations), or itraconazole [575, 2163]. The ability of voriconazole to effectively treat invasive aspergillosis and to reduce associated mortality was recently demonstrated by a large well-conducted randomized trial and is particulary noteworthy. A large number of new investigational drugs posaconazole, ravuconazole, caspofungin, FK463, and anidulafungin have activity against Aspergillus spp. and are being extensively evaluated. Caspofungin was also recently licensed in the United States for treatment of invasive aspergillosis in patients who are refractory to, or intolerant of other therapies (i.e., amphotericin B, lipid formulations of amphotericin B, and/or itraconazole) . However, despite these advances in therapy, the invasive forms of aspergillosis are often associated with significant morbidity and mortality .
Selection of therapy also needs to consider the certainty of the diagnosis. Voriconazole, itraconazole, the investigational azoles with anti-mould activity, and amphotericin B all possess a reasonably broad-spectrum of activity against Aspergillus and the related hyaline moulds. Their activity does, however, vary for the agents of zygomycosis, with N/A(L):posaconazole being the azole with the most reliable activity against this class of fungi. The echinocandin N/A(L):glucan synthesis inhibitors (caspofungin, FK463, and anidulafungin) possess a narrower spectrum of activity and should only be used if the infection is known to be due to Aspergillus spp.
The tissue reaction in aspergillosis is acute suppurative inflammation with areas of ischemic necrosis. The fungus proliferates as septate hyphae 2.5-4.5 µm in diameter . The hyphae can be characterized as branching dichotomously (approximately 45°C angle) with the overall appearance of an army on the march. The hyphae may branch irregularly and appear similar to hyphae found in zygomycosis. Blood vessel invasion, thrombosis, infarction, and dissemination are extremely common.
Clinical material, such as fluids, sputa, or tissue, is mounted in 10% KOH. Long, branching, hyaline, septate hyphae approximately 3.0 µm in diameter typify aspergillosis. The demonstration of hyphae in the clinical specimen and the repeated recovery of the same species of Aspergillus in culture is critical in supporting the diagnosis of aspergillosis. It must always be remembered that a number of other fungi can be morphologically identical to Aspergillus in tissue. On rare occasions, the hyphae of an Aspergillus sp. may have lateral conidia in tissue.
Inoculate the clinical material onto Sabouraud glucose agar, Inhibitory Mould Agar (IMA) or other proper medium with antibiotics (gentamicin or chlorampenicol) and incubate at 30°C. Aspergillus spp are susceptible to cycloheximide, hence they will not grow on media containing this antimicrobial agent. Discard negative cultures after 4 weeks.
Mycology (principal fungi)
Detection of galactomannan antigen in serum
The mortality rate of invasive aspergillosis is as high as 50-100% and definitive diagnosis by culture may take as long as 4 weeks. Thus, early diagnosis is of remarkable significance for earlier initiation of antifungal therapy and reduction of mortality rates. Detection of galactomannan antigen, an exoantigen of Aspergillus, has recently been shown to be a useful screening test for early diagnosis of invasive aspergillosis. Platelia Aspergillus EIA (Bio-Rad Laboratories) is a commercially available kit used to detect galactomannan antigen in body fluids. This method can detect as little as 1 ng/ml of galactomannan in the tested sample. Serum is the most frequently tested specimen and appears to provide highest sensitivity. Use of other samples such as bronchoalveolar lavage  and cerebrospinal fluid [2315, 2333] also appears to provide promising results.
Galactomannan antigen positivity is among the microbiological diagnostic criteria proposed by European Organization for Research and Treatment of Cancer (EUORTC) and Invasive Fungal Infections Cooperative Group and the National Institute of Allergy and Infectious Diseases Mycoses Study Group (MSG) for diagnosis of invasive aspergillosis . This tool continues to gain acceptance: the US Food & Drug Administration approved the marketing of Platelia Aspergillus EIA kit in USA on 16 May 2003.
Galactomannan antigen positivity can be detected 5-8 days (average) before clinical signs develop (in 65.2% of patients), findings on chest X-ray are visible (in 71.5% of patients) and culture results become positive (in 100% of patients) . The test should be used as a screening test for patients at high risk of developing invasive aspergillosis [1407, 1408]. Detection of positive results particularly in two consecutive serum samples provides strong support for the diagnosis of invasive aspergillosis. Platelia Aspergillus EIA can also be used for follow-up of clinical response to antifungal therapy. The titer of the antigen tends to decrease in case of clinical response , except for patients who are treated with an N/A(L):echinocandin compound .
The overall sensitivity and specificity of the method were 80.7% and 89.2%, respectively, in the dataset submitted to the US FDA. False positive reactions have been observed in 1-18% of the tested samples and may be due to cross reactivity or false positive antigenemia. Cross reactivity may be due to the existence of other fungi, such as N/A(L):Penicillium chrysogenum, N/A(L):Penicillium digitatum, N/A(L):Rhodotorula rubra, and N/A(L):Paecilomyces variotii in the tested sample . The mechanism of false positive antigenemia, on the other hand, has not been fully clarified. It appears to be more frequent in children [1031, 1323] and may develop after translocation of galactomannan antigen found in various food stuff (bread, pasta, corn flakes, rice, cake, turkey, sausage, etc.) through the damaged intestinal mucosa . In addition to these, very recent data have shown that the serum samples of patients receiving piperacillin/tazobactam (Zosyn®), an injectable antibacterial combination product from Wyeth Pharmaceuticals, may also yield false positive galactomannan antigen test results. Detection of galactomannan antigen in certain batches of Zosyn® strengthened this finding. Thus, Bio-Rad, the manufacturer of the Platelia Aspergillus EIA kit, now states that positive galactomannan antigen test results in patients treated with Zosyn® should be interpreted cautiously. Since the existence of invasive aspergillosis cannot be ruled out in these patients, other methods should be used for confirmation of the diagnosis. You may refer to the (A):practice caution document (released on November 20, 2003) concerning Zosyn® and the Platelia Aspergillus EIA test kit for more detailed information.
Aspergillus spp. are ubiquitous in the environment. They are especially common in the soil and decaying vegetation.
Susceptibility testing is not routinely used to guide therapy of aspergillosis. We offer both a general discussion of N/A(L):susceptibility testing and a N/A(L):searchable database from which you can retrieve specific results from a variety of published articles.
Related Sites and Therapy Information
- The Aspergillus web site is an excellent and comprehensive resource on all aspects of diagnosis and management of invasive aspergillosis.
- The Infectious Disease Society of America-Mycoses Study Group (IDSA-MSG) Practice Guideline for treating aspergillosis is available at the (E):IDSA website.
Search for Aspergillosis articles